News overview

Biomedical

Rousselot introduces X-Pure®​​​​​​​ GelMA for translational medicine

Rousselot, a Darling Ingredients brand and the global leader of collagen-based solutions(1), takes on the digital challenge and introduces X-Pure® GelMA at Bio Digital 2020. The first GMP-ready range…

Jun 01 • 4 min read
optimizing your excipient screening for vaccine formulation
Biomedical

Join our webinar: “Optimizing Your Excipient Screening for Vaccine Formulation”

On May 28, at 11 am EDT | 8 am PDT | 5 pm CEST, Rousselot Biomedical invites you to attend this live webinar. REGISTER NOW Optimizing Your Excipient Screening for Vaccine Formulation with an…

May 07 • 4 min read
Peptan is highly bioavailable
Health

Rousselot announces: new fundamental study on bioavailability adds to growing scientific literature investigating the mechanisms behind Peptan’s Health Benefits

A new study led by Rousselot in collaboration with INRAe and Triskelion presents pioneering scientific evidence of Peptan’s high bioavailability. Targeted analysis of human serum drawn after Peptan…

Mar 10
Health

The new face of peptan®.com: Rousselot leads the way with the first comprehensive knowledge website in 8 languages on collagen peptides

Irving, United States — [17 February 2020] Rousselot, a Darling Ingredients brand and the global leader of collagen-based solutions[1], announces the revamp of Peptan.com as a multilingual website on…

Feb 18
Biomedical , Health , _News Rousselot , rousselot

Join Rousselot's innovation & inspiration days in April 2020

On April 8 and 9, 2020, Rousselot organize to the 5th edition of its Innovation & Days on ‘Collagens, Solutions & Science’. The two-day event will take place at our Expertise Center in Ghent,…

Feb 10 • 4 min read
X-Pure
Biomedical

Rousselot Biomedical’s X Pure® is changing the game in purified gelatins

Jeff Daelman, Business Development Manager at Rousselot Biomedical, speaks at BIO-Europe® 2019 in Hamburg about X-Pure®, an innovative range of purified gelatins and collagens designed explicitly for…

Nov 27 • 5 min read